Understanding the clinical implications of the "non-classical" microbiome in chronic lung disease: a viewpoint
Eur Respir J
.
2024 Feb 22;63(2):2302281.
doi: 10.1183/13993003.02281-2023.
Print 2024 Feb.
Authors
Steven L Taylor
1
2
,
Aurélie Crabbé
3
,
Luke R Hoffman
4
5
6
,
James D Chalmers
7
,
Geraint B Rogers
8
2
Affiliations
1
Microbiome and Host Health, South Australia Health and Medical Research Institute, Adelaide, Australia steven.taylor@sahmri.com.
2
College of Medicine and Public Health, Flinders University, Bedford Park, Australia.
3
Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
4
Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.
5
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
6
Pulmonary and Sleep Medicine, Seattle Children's Hospital, Seattle, WA, USA.
7
Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
8
Microbiome and Host Health, South Australia Health and Medical Research Institute, Adelaide, Australia.
PMID:
38387999
DOI:
10.1183/13993003.02281-2023
No abstract available
Publication types
Editorial
MeSH terms
Humans
Lung
Lung Diseases*
Microbiota*
Grants and funding
K24 HL141669/HL/NHLBI NIH HHS/United States